In this study, tepotinib provided antitumor activity in patients with NSCLC with high-level MET amplification detected by liquid biopsy: ORR was 41.7%, CBR was 45.8%, and median DOR was 14.3 months. This evidence concerns the gene MET and non-small cell lung carcinoma.